ID   CCF-RC1
AC   CVCL_9703
SY   CCF-RC-1
DR   Wikidata; Q54808963
RX   PubMed=2582448;
RX   PubMed=7591954;
CC   Population: Caucasian.
CC   Doubling time: 34 hours (PubMed=2582448).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9704 ! CCF-RC2
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 11
//
RX   PubMed=2582448;
RA   Hashimura, Takayuki
RA   Tubbs, Raymond Roy
RA   Connelly, Robert
RA   Caulfield, Michael J.
RA   Trindade, C.S.
RA   McMahon, James T.
RA   Galetti, Tommaso Prayer
RA   Edinger, Mark
RA   Sandberg, Avery Aba
RA   Dal Cin, Paola S.
RA   Sait, Sheila N. Jani
RA   Pontes, Jose Edson
RT   "Characterization of two cell lines with distinct phenotypes and
RT   genotypes established from a patient with renal cell carcinoma.";
RL   Cancer Res. 49:7064-7071(1989).
//
RX   PubMed=7591954; DOI=10.1111/j.1349-7006.1995.tb03087.x; PMCID=PMC5920923;
RA   Kinoshita, Hidefumi
RA   Yamada, Hitoshi
RA   Ogawa, Osamu
RA   Kakehi, Yoshiyuki
RA   Osaka, Mitsuhiko
RA   Nakamura, Eijiro
RA   Mishina, Mutsuki
RA   Habuchi, Tomonori
RA   Takahashi, Rei
RA   Sugiyama, Taketoshi
RA   Yoshida, Osamu
RT   "Contribution of chromosome 9p21-22 deletion to the progression of
RT   human renal cell carcinoma.";
RL   Jpn. J. Cancer Res. 86:795-799(1995).
//